Evidence map›Paper›PMID 17002504›Full record

ArticlePLoS medicine2006

River blindness: a success story under threat?

María-Gloria Basáñez, Sébastien D S Pion, Thomas S Churcher, Lutz P Breitling, Mark P Little, Michel Boussinesq

Registry-linked trialAbstract read
In one paragraph

Article in PLoS medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03238131 (Comparison of Ivermectin Alone With Albendazole), which is not on this map. Cited by 105 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03238131 phase3completednot on this mapstarted 2012, after this paper: background citation

Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis

TypeinterventionalSponsorUniversity Hospitals Cleveland Medical CenterRan2012 to 2016Enrolled272ConditionsOnchocerciasisArmsIvermectin, Albendazole
3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Pooled it
  4. Pooled it
  5. Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Spatial and seasonal dynamics ofParasite epidemiology and control · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

María-Gloria BasáñezDepartment of Infectious Disease Epidemiology, Imperial College of Science, Technology and Medicine, London, United Kingdom. m.basanez@imperial.ac.uk
Sébastien D S Pion
Thomas S Churcher
Lutz P Breitling
Mark P Little
Michel Boussinesq

Funding

Medical Research Council G0200123Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Developing CountriesAfricaAntiparasitic AgentsCommunity Health ServicesCost of IllnessGlobal HealthHealth Care CostsHumansInternational CooperationIvermectinOnchocerciasis, OcularSocioeconomic FactorsAntiparasitic AgentsIvermectin

Identifiers

PMID17002504
PMCPMC1576321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.